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ABSTRACT
Aging is associated with a rising incidence of cutaneous squamous cell 
carcinoma (cSCC), an aggressive skin cancer with the potential for local invasion 
and metastasis. Acquisition of a senescence-associated secretory phenotype (SASP) 
in dermal fibroblasts has been postulated to promote skin cancer progression in 
elderly individuals. The underlying molecular mechanisms are largely unexplored. We 
show that Chemerin, a previously unreported SASP factor released from senescent 
human dermal fibroblasts, promotes cSCC cell migration, a key feature driving tumor 
progression. Whereas the Chemerin abundance is downregulated in malignant cSCC 
cells, increased Chemerin transcripts and protein concentrations are detected in 
replicative senescent fibroblasts in vitro and in the fibroblast of skin sections from 
old donors, indicating that a Chemerin gradient is built up in the dermis of elderly. 
Using Transwell® migration assays, we show that Chemerin enhances the chemotaxis 
of different cSCC cell lines. Notably, the Chemerin receptor CCRL2 is remarkably 
upregulated in cSCC cell lines and human patient biopsies. Silencing Chemerin in 
senescent fibroblasts or the CCRL2 and GPR1 receptors in the SCL-1 cSCC cell line 
abrogates the Chemerin-mediated chemotaxis. Chemerin triggers the MAPK cascade 
via JNK and ERK1 activation, whereby the inhibition impairs the SASP- or Chemerin-
mediated cSCC cell migration.
Taken together, we uncover a key role for Chemerin, as a major factor in the 
secretome of senescent fibroblasts, promoting cSCC cell migration and possibly 
progression, relaying its signals through CCRL2 and GPR1 receptors with subsequent 
MAPK activation. These findings might have implications for targeted therapeutic 
interventions in elderly patients.
INTRODUCTION
Cutaneous squamous cell carcinoma (cSCC) 
represents the second most common type of skin 
cancer worldwide with increasing incidence in elderly 
individuals [1]. cSCC develops through a multistep 
process, in which the accumulation of mutations and 
genetic alterations mainly drive the initiation step [2], 
while the cellular and molecular alterations of the 
surrounding microenvironment support the promotion 
and progression steps [3]. Exposure to ultraviolet 
(UV) radiation is the main cause for DNA damage and 
mutations in epidermal keratinocytes as well as in dermal 
fibroblasts underneath the epidermis [4, 5]. Mutations in 
the epidermal stem/progenitor cells affecting oncogenes 
like Ras or tumor suppressor genes such as p53 are 
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frequently causal for cSCC initiation [2]. In addition, the 
DNA damage response pathways in dermal fibroblasts 
lead to the activation of p53 and p16INK4a and induction 
of cellular senescence. Senescent fibroblasts have been 
shown to accumulate over the life span in the skin 
of rodents, non-human primates and humans [6–8]. 
Senescent fibroblasts adopt a senescence-associated 
secretory phenotype (SASP), consisting of inflammatory 
cytokines, chemokines and matrix remodeling factors that 
- depending on the biological context - may contribute 
to tumor suppression or progression [7, 9]. Though 
the senescent human fibroblasts have been reported to 
accelerate epidermal tumorigenesis in nude mice, the 
underlying mediators are largely unknown [10]. It has 
been proposed that the activation of oncogenic Ras in 
aged murine skin causes excessive cellular senescence, 
epidermal stem cell dysfunction, enhanced inflammation, 
and immune cell skewing towards a T helper cell type 2, 
eventually resulting in epidermal dysplasia and cSCC 
progression [11].
Secreted chemokines are major components of the 
SASP [12], which play key roles in tumor cell motility, 
invasion and metastasis [13]. The involvement of 
chemokine/chemokine receptors in tumor metastasis was 
first dissected by Müller and colleagues. These authors 
uncovered the contribution of CXCL12/CXCR4 in breast 
cancer metastasis [14]. Subsequently, additional evidence 
substantiated the role of chemokines in tumor progression, 
particularly in tumor cell migration and invasion 
[13, 15, 16]. In this context, the CCL21/CCR7 axis has 
been proposed to be involved in the development of lymph 
node metastasis in a variety of different tumors [17–19]; 
and the CXCL6/CXCR6 axis has been shown to induce the 
progression of prostate [20] and breast cancers [21]
Of note, we found a remarkable upregulation 
of C-C chemokine receptor-like 2 (CCRL2) in cSCC 
primary tumors and cell lines as compared to the normal 
keratinocytes, their benign counterparts. CCRL2 has been 
earlier suggested to contribute to glioblastoma (GBM) 
cell migration and invasion [22] as well as to colorectal 
liver metastasis [23]. The known ligand for CCRL2 is the 
18-kDa chemoattractant protein Chemerin [24]. Chemerin, 
also known as tazarotene-induced gene 2 (TIG2) [25] and 
retinoic acid receptor responder 2 (RARRES2), binds to 
two other independent receptors termed chemokine-like 
receptor 1 (CMKLR1 or ChemR23) [26] and G-protein 
coupled receptor 1 (GPR1) [27]. Overexpression of 
Chemerin was linked to enhanced tumor angiogenesis and 
poor clinical outcome in oral squamous cell carcinoma 
(OSCC) [28], and progression of esophageal squamous 
cell carcinoma (ESCC) [29, 30]. Increased serum 
Chemerin level was associated with cellular invasiveness 
in gastric cancer [31]. Here, we report markedly elevated 
Chemerin concentrations in the SASP of human senescent 
dermal fibroblasts, and uncover a previously unreported 
role for the Chemerin/CCRL2 axis in promoting MAPK-
dependent cSCC migration.
Our findings may have substantial clinical impact 
for the development of therapeutic strategies to counteract 
the SASP-induced progression of cutaneous squamous cell 
carcinoma in elderly patients.
RESULTS
The secretome of senescent fibroblasts enhances 
migration and invasion of cutaneous squamous 
carcinoma cell lines in vitro
Enhanced cell motility constitutes an important step 
in cancer progression and metastasis [32]. As the incidence 
of cSCCs increases with age and senescent fibroblasts have 
been suggested to play a causal role in cSCC progression, 
we investigated the paracrine effects of senescent human 
dermal fibroblasts (HDFs) on cSCC cell migration and 
invasion. Conditioned medium (CM) was harvested from 
senescent and young (early passage) fibroblasts to assess 
its chemotactic activity on migration of normal human 
keratinocytes and different cSCC cell lines (SCL-1, SCC-
13, SCC-12B2 and A431 cells) in a Transwell® chamber 
migration assay. As depicted in Figure 1A and 1B, 
increased cSCC cell migration was observed in response 
to senescent CM of FF95 fibroblast strain compared to 
young CM. Normal keratinocytes did not migrate when 
exposed to senescent or young fibroblast CM, as opposed 
to the strong chemotaxis in response to collagen (positive 
control) [33]. These results were reproduced using CM of 
all three independent replicative senescent HDF strains 
(FF95, FFRa and FFPia), confirming that the secretome 
of all tested senescent HDFs consistently enhanced the 
migration of SCL-1 tumor cells (Figure 1C). Although 
to a different extent, a robust migratory response of 
different cSCC cell lines was induced by CM of senescent 
fibroblasts of different strains (Figure 1C), these data 
indicate that the observed enhanced migratory response 
is similar for all tested cSCC cell lines and senescent 
fibroblast strains and most likely constitutes a general 
mechanism of SASP-induced migration. Interestingly, CM 
of primary stromal fibroblasts derived from cSCC patients 
at old age displayed similar migratory-promoting effects 
on SCL-1 cells (Supplementary Figure S1).
Moreover, we observed an increased cell invasion 
through a reconstituted basement membrane (Matrigel®) in 
response to conditioned medium of senescent fibroblasts 
(FF95 CM) in SCL-1 cancer cells in vitro (Supplementary 
Figure S2). This phenotype has been previously reported 
to be mediated through the secretion of active MMP-2 by 
senescent cancer-associated fibroblasts [34].
The chemoattractant Chemerin is upregulated in 
senescent fibroblasts
Earlier we attempted to define the secretome of 
senescent fibroblasts using an antibody array, mainly 
confirming the previously published SASP factors 
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[6, 35, 36]. Even though these SASP factors, such as 
CCL5/RANTES [37, 38], were able to significantly 
stimulate cSCC cell migration (Supplementary Figure S3), 
they were produced at even higher levels by SCC cells 
themselves in an autocrine manner, as have been 
previously reported [39, 40]. Therefore, any significant 
paracrine contribution from senescent dermal fibroblasts 
was ruled out.
In a complementary attempt to identify novel 
SASP factors, we performed PCR array analysis of the 
chemokine receptors in cSCC cells (Supplementary 
Figures S4 and S5). Of note, we found a remarkable 
upregulation of CCRL2 receptor in all tested cSCC cell 
lines, a chemokine receptor processing high affinity for 
Chemerin, the ligand which had not been identified with 
the conventional screening strategies.
Interestingly, the RARRES2 transcripts encoding 
the Chemerin protein were increased in all tested 
senescent fibroblast strains compared to young 
fibroblasts (Figure 2A). By contrast, with the exception 
of the A431 cell line, cSCC cells displayed significantly 
lower RARRES2 mRNA transcripts with a strong 
downregulation of Chemerin expression as compared to 
normal cells (keratinocytes) and fibroblasts (Figure 2A).
Enzyme-linked immunosorbent assay (ELISA) 
revealed increased levels of secreted Chemerin in CM 
of senescent fibroblasts compared with CM of young 
fibroblasts with a very low expression in keratinocytes 
to almost undetectable in cSCC cells (Figure 2B). 
These data were further confirmed by immunostaining 
(Figure 2C and 2D), showing significantly higher number 
of Chemerin-positive fibroblasts (33.35 % ± 8.22 of total 
dermal cells) in skin biopsies derived from aged healthy 
human individuals (age 76 ± 10 years, n = 15 healthy 
donors) as compared to young humans (11.82 % ± 6.82 
total dermal cells, age 21 ± 8 years, n = 13 healthy donors). 
Figure 1: Secretome of senescent fibroblasts enhances the migration of squamous cell carcinoma lines. Cell motility was 
evaluated using the Transwell® chamber migration assay. The lower compartments of the chamber were loaded with conditioned medium 
(CM) of senescent (SEN) and corresponding young (YNG) fibroblasts and incubated for 14 h at 37°C. DMEM containing 10% fetal 
bovine serum (FBS) and collagen type I at a concentration of 50 μg/ml served as positive controls. DMEM served as a negative control. 
Cells stained purple by Diff-Quick staining kit and counted under light microscopy at ×100 magnification (A) Representative images 
(×200 magnification, scale bars = 50 µm) showing migrated SCL-1 cells (pointed with red arrows) at the downside of the membrane 
in response to CM from senescent vs. young fibroblasts. Quantifications of cell migration proved that (B) Senescent (SEN) conditioned 
media of human dermal fibroblast strains FF95, FFRa and FFPia enhanced the migration of SCL-1 tumor cells compared with young 
(YNG) counterparts. Data are shown as mean ± S.D for n = 3 replicates. ***p < 0.001 calculated by unpaired student t-test between SEN 
CM-treated and YNG CM- treated groups for each fibroblast strains. (C) Conditioned media of FF95 senescent fibroblasts increased the 
migration of all tested tumor cells (SCL-1, SCC-12B2, SCC-13 and A431) but had no effect on normal keratinocytes. Data are shown 
as mean ± S.D for n = 3 replicates; Graphs represent one of the three independent experiments; *p < 0.05, **p < 0.01 and ***p < 0.001 
calculated by unpaired student t-test between SEN CM-treated and YNG CM- treated groups for each cell line; HPF = ×100 magnification. 
(Note that due to low standard deviations of some measurements, error bars are not visible for all data points.).
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Of note, immunostaining of skin biopsies derived from 
cSCC patients (Supplementary Figure S6) revealed that 
a large number of Chemerin-releasing FSP-1+ fibroblasts 
(30.83 % ± 1.89 of total stromal cells) were present in the 
cSCC tumor stroma of older patients (age 80 ± 5 years, 
n = 5 cSCC patients) as compared to younger cSCC 
patients (16.04 ± 3.2 total stromal cells, age 54 ± 5 years, 
n = 5 cSCC patients). 
Chemerin significantly increases the migration of 
cSCC cell lines in vitro
To determine whether cSCC cells display a 
migratory response to the gradients of recombinant human 
(rh) Chemerin, DMEM containing different concentrations 
of rh Chemerin was placed in the bottom compartment 
of the Transwell® chambers with cSCC cell lines 
seeded on top of the perforated membrane in the upper 
compartment. Chemerin induced a significant increase in 
the migration of all assessed cSCC cell lines compared 
with the untreated control (the number of cells migrating 
spontaneously in the absence of a chemotactic Chemerin 
gradient). The increase in the migratory response occurred 
concentration-dependently, demonstrating a typical 
bell-shaped response curve with maximal numbers of 
migrated cells at concentrations between 20 to 40 nM 
Chemerin (Figure 3A–3D). Based on these results the 
concentration of 40 nM Chemerin was used for subsequent 
experiments. Of note, we could show that the migratory 
response of cSCC cells to rh Chemerin alone occurred 
Figure 2: Chemerin is an upregulated SASP factor in human dermal fibroblasts. (A) Graph demonstrating the relative 
RARRES2 (Chemerin gene) mRNA expression in senescent (SEN) vs. young (YNG) fibroblast of different strains (FF95, FFRa and FFPia) 
as defined by qRT-PCR. Data are normalized to the expression level of RARRES2 in keratinocytes, confirming that the senescent fibroblasts 
display the highest, and the cSCC cell lines (SCL-1, SCC12-B2, SCC-13) display the lowest RARRES2 transcripts, respectively. Date are 
shown as mean ± S.D for one of three independent experiments of biological replicates (n = 3); *p < 0.05, **p < 0.01 and ***p < 0.001 
calculated by Bonferroni post hoc test after ANOVA. (B) Chemerin secretion was analyzed in the above mentioned cells (normalized to 
5 × 106 cells/ml) using ELISA. Data are shown as mean ± S.E.M for three independent experiments; *p < 0.05, **p < 0.01 and ***p < 0.001 
calculated by Bonferroni post hoc test after ANOVA. (Note that due to low standard deviations of some measurements, error bars are not 
visible for all data points.) (C) Representative photomicrographs of paraffin-embedded human skin sections co-immunostained with anti-
FSP-1 antibody in green and anti-Chemerin antibody in red, depicting higher abundance of Chemerin in skin dermal fibroblasts of aged 
(70-year old), compared to young (23-year old) donors. Nuclei were DAPI-counterstained (blue). Appropriate isotype controls were used to 
determine the background. Scale bars = 50 µm at ×400 magnification; Dashed lines delineate epidermis (E) from dermis (D). Orange arrows 
point to the Chemerin-positive fibroblasts. Orange boxes depict the magnified area. (D) Graph representing the quantification of Chemerin-
positive fibroblasts (shown by FSP-1 marker) in the skin dermis of old healthy individuals (76 ± 10 year, n = 15 donors) and young (21 ± 8 year, 
n = 13 donors) calculated from minimum 5 technical replicates. ***p < 0.001 by two-tailed student t-test.
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at a physiological Chemerin concentration of 20–40 nM 
(< 150 cells/HPF), while the CM of senescent fibroblasts 
induced an even stronger migratory response of cSCC 
cells (> 300 cells/HPF), suggesting that other SASP 
factors in addition to Chemerin are contributing. In fact, 
we identified the SASP factor RANTES/CCL5 to induce 
cSCC cell migration (Supplementary Figure S3).
Of note, Chemerin does not induce cSCC cell 
proliferation in vitro as shown by MTT test and BrdU 
incorporation assays (Supplementary Figures S7A–S7E). 
These observations provide convincing evidence in favor 
of the hypothesis that migration and proliferation are 
mutually exclusive in cancer cells [41, 42]. 
Chemerin depletion diminishes the potential 
of senescent fibroblast-derived SASP to induce 
cSCC cell migration
To further assess whether Chemerin contributes 
to the SASP-induced migratory response of cSCC cells, 
Chemerin was depleted from senescent fibroblasts 
using Chemerin-specific silencing RNAs. Two days 
after transfection, RARRES2 transcripts and Chemerin 
secretion dramatically decreased to less than 5% of the 
mock-treated fibroblasts as shown with qRT-PCR and 
ELISA (Figure 3E and 3F), respectively. Of note, CM 
derived from Chemerin-silenced senescent fibroblasts 
showed a significant reduction (over 30%) in stimulating 
the migratory response of SCL-1 cells (Figure 3G). This 
finding was confirmed with four independent silencing 
RNAs, indicating that Chemerin is one of the major SAPS 
factors of senescent dermal fibroblasts, which induces 
cSCC cell migration.
The Chemerin receptor CCRL2 is upregulated 
in cSCC cells
As mentioned above, the higher level of CCRL2 
receptor expression was detected on cSCC cells compared 
with normal cells using the PCR array analysis.
We further employed qRT-PCR, Western blot and 
flow cytometry analysis to evaluate the expression of 
CCRL2 and other Chemerin receptors including CMKLR1 
and GPR1 in cSCC cell lines and normal keratinocytes 
(Figure 4). Notably, CCRL2 mRNA was significantly 
increased in all cSCC cells (> 25-fold) compared to 
normal keratinocytes (Figure 6A, 6B and Supplementary 
Figures S4 and S5). GPR1 mRNA was also detectable in 
cSCC cell lines, although the transcripts were substantially 
less abundant in comparison with normal keratinocytes 
(Figure 4A and 4C).
Transcripts of CMKLR1 were neither detected in 
cSCC cell lines, nor in keratinocytes (Figure 4A).
Using flow cytometry analysis, the cell surface 
expression of CCRL2, GPR1 and CMKLR1 was analyzed, 
revealing high expression levels of CCRL2 (77.7% ± 4.6) 
and low expression of GPR1 (3.55% ± 0.87) on SCL-1 
cells in comparison to a significantly lower level of 
CCRL2 (8.7% ± 1.1) and higher GPR-1 (13.1% ± 7.92) 
on keratinocytes (Figure 4D and 4E). Neither SCL-1 cells 
nor keratinocytes expressed CMKLR1 at detectable levels 
(data not shown).
Western blot analysis confirmed the upregulation 
of CCRL2 at the protein level; Consistent with the FACS 
analysis and qRT-PCR data, SCL-1, SCC-12B2, SCC-13 
and A431 strongly expressed CCRL2 compared with 
normal keratinocytes (Figure 4F).
To confirm the clinical significance of CCRL2 
expression, primary tumors from cSCC patients (n = 8) 
were subjected to immunofluorescence staining. CCRL2 
staining was mainly observed in the invading edges of 
cSCC cells. By contrast, in normal skin from healthy 
individuals, epidermal keratinocytes displayed no or very 
low CCRL2 expression (Figure 4G).
Hence, CCRL2 constitutes the most abundant 
Chemerin receptor in cSCC cells, suggesting that it may 
favor the enhanced migration of cSCC tumor cells to 
invade the Chemerin-rich dermis.
Role of CCRL2 and GPR1 in Chemerin-mediated 
cSCC cell migration
Enhanced CCRL2 expression on cSCC cells 
indicates that this receptor might play a role in the 
migratory response to Chemerin. We therefore assessed 
whether the knockdown of CCRL2 expression using 
lentivirus-based short hairpin RNAs (shRNAs) could 
suppress the cSCC cell migration. Likewise, the GPR1 
receptor was also lentivirally-silenced from SCL-1 cells. 
Successful transcriptional silencing of GPR1 and CCRL2 
(> 50%) in sorted populations of mCherry-positive 
(GPR1) or eGFP-positive (CCRL2) SCL-1 cells (Figure 
5A–5B) was verified using qRT-PCR (Figure 5C–5D). 
The GPR1-silenced and CCRL2-silenced cells were 
subjected to Transwell® chamber migration assays. Relative 
cell migration (Chemerin/Untreated) was calculated in each group 
as the ratio of cells migrated towards a Chemerin gradient 
(40 nM) to the cells migrated randomly in the negative 
control (untreated cells in serum-free DMEM). The results 
showed that the directed cell migration in response to 
rh Chemerin was reduced to a similar level as random 
migration in GPR1-knockdown or CCRL2-knockdown cells 
(Chemerin/Untreated ~ 1) as compared to the scrambled-transfected 
cells (Chemerin/Untreated > 2). In other words, the shRNA-
mediated silencing of either CCRL2 or GPR1 blocked 
the Chemerin-induced migration by > 50% in SCL-1 
cells in comparison to scrambled control (Figure 5E). 
Consistent results were achieved with both independent 
shRNAs targeting CCRL2 and GPR1 (Figure 5E). 
These results support the notion that CCRL2 and 
GPR1 constitute the responsible receptors for Chemerin-
induced cSCC cell migration. This is consistent with our 
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observation that keratinocytes, despite expressing high 
levels of GPR1, are not responsive to Chemerin, probably 
due to the very low CCRL2 expression (data not shown).
Activation of MAPK signaling pathway in 
response to Chemerin
To further elucidate the molecular mechanism 
underlying Chemerin-induced cSCC cell migration, we 
explored signaling pathways downstream of the Chemerin 
receptors CCRL2 and GPR1, both belonging to the family 
of G-protein coupled receptors (GPCRs). We employed 
a GPCR Cignal® Finder Array, and transfected SCL-1 
cells with luciferase reporter DNA constructs containing 
transcription factor elements (TFEs), and assessed the 
reporter activities in response to rh Chemerin stimulation. 
Rh Chemerin enhanced Mitogen-activated protein kinase 
(MAPK) activities of both c-Jun N-terminal kinases (JNK) 
and extracellular-signal-regulated kinase (ERK) signaling 
pathways in SCL-1 cells after an incubation period of 1 h 
(Figure 6A). The activation of JNK and ERK persisted for 
up to 24 hours (data not shown).
Activation of MAPK pathways in response to rh 
Chemerin was further confirmed at the protein level by 
Western blot analysis. Increased phosphorylated forms 
of ATF2, SEK1, c-Jun and ERK1/2, were detected in rh 
Chemerin-treated SCL-1 cells compared with untreated 
cells (Figure 6B).
Figure 3: Chemerin stimulates migration of squamous carcinoma cell lines. Graphs demonstrating the bell-shape curves of 
chemotactic response to the increased concentrations of Chemerin in (A) SCL-1, (B) SCC-12B2, (C) SCC-13 and (D) A431 cells using 
the Transwell® chamber migration assay. Date are shown as mean ± S.D for one of three independent experiments with n = 4 replicate 
wells; n.s. = non-significant, *p < 0.05, **p < 0.01 and ***p < 0.001 in comparison to random migration control with no Chemerin 
treatment calculated by Bonferroni post hoc test after ANOVA. The role of Chemerin in mediating cSCC cell migration was confirmed by 
silencing the Chemerin gene (RARRES2) in senescent fibroblasts and assessing their ability to induce SCL-1 cell migration (E) Transcript 
level of RARRES2 was quantified by qRT-PCR in senescent fibroblasts 42 h post treatment with siRNAs, confirming the successful gene 
silencing compared to scrambled control. Data are shown as mean ± S.E.M from three independent experiments. ***p < 0.001 calculated by 
Bonferroni post hoc test after ANOVA. (F) Chemerin protein level (normalized to 5 × 106 cells/ml) was measured 48 hours after treatment 
with siRNAs or scrambled control. Data are shown as mean ± S.E.M from four independent experiments; *p < 0.05 calculated by Bonferroni 
post hoc test after ANOVA. (G) Conditioned media derived from Chemerin-silenced fibroblasts (siRNA 1, 2, 5 and 6) were used to induce 
the migration of SCL-1 cells using the Transwell® chamber migration assay. Conditioned media derived from mock-treated fibroblasts 
(Scrambled) and senescent fibroblasts with no treatment (control) were used as controls. Shown is one representative of four independent 
experiments, each with triplicate samples. *p < 0.05, **p < 0.01 and ***p < 0.001 calculated by Bonferroni post hoc test after ANOVA.
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Figure 4: CCRL2 is the upregulated Chemerin receptor in cutaneous carcinoma cell lines and human squamous cell 
carcinoma. (A) Heat map representing the gene expression profile of Chemerin receptors CCRL2, GPR1 and CMKLR1. Relative gene 
expression was calculated from all three independent experiments normalized to the level of Actin housekeeping gene expression, and 
relative to the mean expression in normal keratinocytes. Genes were rank-ordered by Pearson correlation and depicted by a pseudo color 
scale based on qRT-PCR delta-CT values with green and red demonstrating low and high mRNA abundance, respectively. CMKLR1 had 
very low to no mRNA transcripts; CCRL2 was highly upregulated in cSCC cells; and GPR1 was either downregulated or not changed in 
cSCC cells compared to keratinocytes. (B–C) Graphs depict the relative fold changes of CCRL2 and GPR1 mRNA expression in cSCC 
lines compared with normal keratinocytes as defined by qRT-PCR. Shown is one representative of three independent experiments, each 
with triplicate samples. *p < 0.05, **p < 0.01 and ***p < 0.001 calculated by Bonferroni post hoc test after ANOVA. (Note that due to 
low standard deviations of some measurements, error bars are not visible for all data points.) (D–E) Cell surface expressions of CCRL2, 
GPR1 and CMKLR1 were assessed by flow cytometry analysis in SCL-1 cells and normal keratinocytes. Displayed are the representative 
fluorescence histograms depicting the relative fluorescence intensity of cells stained with (D) APC-conjugated anti-CCRL2 and (E) A488-
conjugated anti-GPR1 antibodies (black histograms) compared with isotype control antibodies conjugated with corresponding fluorochromes 
(gray histograms). The expression of CMKLR1 was not detectable (not shown). Bar charts represent one of three independent experiments 
demonstrating the mean percentage ± S.D. for (d) CCRL2-positive and (E) GPR1-positive SCL-1 cells vs. keratinocytes. *p < 0.05, 
**p < 0.01 and ***p < 0.001 calculated by two-tailed student t-test (n = 8 biological replicates). (F) Representative Western bot analysis of 
cSCC and keratinocyte cell lysates, confirming the elevated protein level of CCRL2 in cSCC cells compared with normal keratinocytes. (G) 
Representative photomicrographs of skin biopsies derived from patients suffering from invasive cSCC vs. normal healthy controls stained 
for Hematoxylin and Eosin (H & E), CCRL2 in red and cytokeratin in green. Nuclear was stained with DAPI (blue). Arrows show the 
CCRL2-positive cells. Appropriate isotype controls were used to determine the background. H&E images were taken at ×200 magnification 
and immunofluorescence at ×400 magnification; Scale bars = 50 µm. Orange boxes depict the magnified area. (H) Graph representing the 
quantification of CCRL2-positive epidermal-derived cells in the skin specimens of patients suffering from cSCC (n = 8) vs. normal healthy 
individuals (n = 6). **p < 0.01 by two-tailed student t-test.
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Inhibition of MAPK pathway abrogates cSCC 
cell migration
Next we addressed the question whether the 
inhibition of the MAPK pathway can suppress Chemerin- 
or SASP-mediated migration of cSCC tumor cells. 
Notably, the ERK1/2 inhibitor FR180204 [43], and 
the JNK inhibitor SP600125 [44], in a concentration-
dependent manner, mitigated the ability of senescent CM 
to induce SCL-1 cell migration. The SASP-mediated 
SCL-1 cell migration was almost completely abolished 
following treatment with 30 µM FR180204 and to a lesser 
extent with SP600125 (Figure 6C). BIRB796, a specific 
p38 inhibitor [45, 46], did not significantly decrease the 
SASP-induced migration of SCL-1 cells.
A concentration of 10 μM FR180204 or SP600125 
but not BIRB796 blocked the rh Chemerin-induced 
SCL-1 cell migration (> 70%) in comparison to control 
(Figure 6D), suggesting that Chemerin regulates the 
cSCC cell migration through ERK1/2 and JNK- but 
independently of the p38 MAPK pathway.
The used concentrations were non-toxic as shown 
by MTT assays (Supplementary Figure S7F).
DISCUSSION
Accumulating evidence suggests that the 
senescence-associated secretory phenotype (SASP) is 
one of the major causal links between the age-associated 
alterations in tissue microenvironment and the rising 
Figure 5: CCRL2 and GPR1 receptors are required for Chemerin-stimulated squamous cell carcinoma migration. 
In order to study the role of Chemerin receptors in mediating cSCC cell migration, SCL-1 cells were transduced with lentivirus encoding 
shRNAs against GPR1 and CCRL2. The GPR1 shRNA-expressing lentiviral vector and the CCRL2 shRNA-expressing lentiviral vector 
contained mCherry and eGFP proteins, respectively, which enabled us to isolate positively-transduced cells using fluorescence-activated 
cell sorting (FACS). (A–B) Representative FACS dot plots showing the final gating strategies to sort mCherry- and eGFP-expressing 
cells. (C–D) The efficiency of CCRL2 and GPR1 knockdown in SCL-1 cells was validated by qRT-PCR. Data are presented as bar charts, 
representing the mean expression fold changes relative to scrambled controls ± S.D. *p < 0.05, **p < 0.01 and ***p < 0.001 calculated by 
ANOVA (n = 3). (E) Graph indicating that CCRL2 and GPR1 silencing suppresses Chemerin-mediated SCL-1 cell migration. The relative 
migration (Chemerin/Untreated) was calculated in each group as the ratio of cells migrated towards the Chemerin gradient (40 nM) to the cells 
migrated randomly in the negative control (serum-free DMEM). Data are presented as Mean ± S.E.M. for 3 independent experiments; 
*p < 0.05, **p < 0.01 and ***p < 0.001 calculated by Bonferroni post hoc test after ANOVA.
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incidence of cancer [9, 11, 47]. It has been recently shown 
that the SASP from senescent stromal fibroblasts inhibits 
the RhoA/ROCK/myosin-dependent cell contractility 
leading to aggressive cell motility in human breast cancer 
cells [48]. However, the exact key SASP factors and the 
mechanisms involved in cSCC cell migration have not 
been fully elucidated. Here we showed that Chemerin, 
released by senescent dermal fibroblasts, exerts a strong 
chemotactic activity in cSCC cells and thus contributes 
to enhanced cSCC cell migration via activation of MAPK 
pathway. These findings were corroborated by our 
observation that the putative Chemerin receptor, CCRL2, 
was remarkably upregulated in cSCC tumor cells, which, 
together with the GPR1 receptor, mediated the response 
to Chemerin.
In general, Chemerin is known to be involved 
in regulating adipogenesis and lipid metabolism [49], 
inflammation and leukocyte trafficking [50], and 
endothelial angiogenesis and MMP production [51]. 
Dysregulated expression of Chemerin has been correlated 
Figure 6: Role of MAPK signaling pathway in the regulation of Chemerin-mediated cell migration. (A) In order to define 
the signaling pathway activated by Chemerin, we used a G-protein couple receptor (GPCR) Cignal Finder® Reporter Array consisting of 
inducible transcription factor response constructs encoding the firefly luciferase reporter gene. SCL-1 cells were transfected with each 
reporter constructs and further treated with DMEM containing 40 nM rh Chemerin or no Chemerin (control) for 1 hour. The dual-luciferase 
assay was developed and the results were expressed as the percentage of relative luminescence signal according to the manufacturer’s 
instructions. Results highlighted that Chemerin activates JNK and ERK1/2 MAPK signaling pathway. Shown is a representative of three 
independent experiments presented as Mean ± S.D (n =3). *p < 0.05 calculated by unpaired student t-test. (Note that due to low standard 
deviations of some measurements, error bars are not visible for all data points.) (B) To confirm the Cignal Finder® Reporter Array data, 
SCL-1 cells were cultured in the presence and absence of 40 nM rh Chemerin for 30 and 60 minutes and protein lysates were analyzed 
by Western blot for phosphorylated and total amounts of MAPK key proteins. (C) We investigated whether inhibition of MAPK pathway 
dampens the migration of SCL-1 cells stimulated by Chemerin-rich conditioned media of senescent fibroblasts. The graph represents 
the concentration-dependent inhibition of SCL-1 cell migration in response to senescent fibroblast CM by SP600125 (JNK inhibitor), 
FR180204 (ERK1/2 inhibitor) and BIRB796 (P38 inhibitor). DMSO served as a vehicle control. Data are presented as Mean ± S.E.M. for 
3 independent experiments; *p < 0.05, **p < 0.01 and ***p < 0.001 in comparison to DMSO control calculated by Bonferroni post hoc 
test after ANOVA; HPF= ×100 magnification (D) Bar graph showing the effect of MAPK inhibitors (10 μM) on Chemerin-mediated SCL-1 
cell migration. Data are presented as mean ± S.E.M. for 3 independent experiments; ***p < 0.001 calculated by Bonferroni post hoc test 
after ANOVA. HPF= ×100 magnification.
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with tumor progression in glioma [52], squamous cell 
carcinoma of oral tongue [28], esophageal cancer [30] and 
with tumor suppression in melanoma [53]. However, the 
biological effects of differential expression of Chemerin in 
tumor and stromal cells in the context of tumor migration 
have not been sufficiently explored. In the present study, 
based on the following findings, we conclude that the 
Chemerin/CCRL2/GPR1 axis is induced by the paracrine 
action of senescent fibroblasts, causing enhanced cSCC 
migration and most likely progression. 
First, a comprehensive transcriptional analysis 
of the chemokine receptor expression in cSCC cell 
lines revealed a remarkable upregulation of CCRL2 
in cSCC cell lines compared to normal keratinocytes 
(Supplementary Figures S4 and S5), a finding which 
was further confirmed with the immunostaining of 
patient tumor biopsies. The elevated CCRL2 expression 
in other tumors including malignant breast cancer [54], 
high grade glioblastoma [22] and cervical carcinoma [55] 
has been previously postulated to be associated with cell 
migration, invasion and poor prognosis, irrespective of 
whether its biological ligands were present or not. Thus, 
the high abundance of CCRL2 receptor on cSCC cell 
surface implicates a crucial role in tumor progression. 
We assumed that the CCRL2 upregulation confers a 
migratory advantage for the epidermal cSCC tumor cells, 
particularly at the invasive front of the epidermis-dermis 
junction, facilitating their migration towards the dermis, 
where a gradient of its high-affinity ligand, Chemerin, 
is established by senescent fibroblasts. Consistent with 
this notion, we detected significantly high Chemerin 
concentrations in senescent dermal fibroblasts in vitro, as 
well as in the dermal fibroblasts of old healthy individuals 
and in the stromal fibroblasts of old cSCC patients in situ. 
This expression pattern was significantly different in the 
young healthy skin, exhibiting lower Chemerin abundance 
in the dermis vs. epidermis, as previously demonstrated 
by Banas et al. [56]. Interestingly, in line with a previous 
publication [57] we found that Chemerin production was 
significantly decreased in cSCC cells compared to normal 
keratinocytes. 
Second, as to the functional consequences of 
senescence-associated Chemerin upregulation in old skin, 
we showed that rh Chemerin increased the directed cSCC 
cell migration; and silencing of Chemerin in senescent 
fibroblasts significantly reduced their potential to induce 
cSCC cell migration. To our knowledge, this is the first 
report on the role of Chemerin in cSCC cell migration, 
although Chemerin has been previously reported to 
promote gastric cancer and esophageal cancer cell 
invasion via induction of VEGF, MMPs and IL-6 [30, 31]. 
Third, we showed that, in the absence of CMKLR1, 
both the CCRL2 and GPR1 receptors are required for 
Chemerin-mediated cSCC cell migration, as silencing 
of either receptors suppressed the migratory response 
of cSCC cells to a Chemerin gradient. In agreement 
with this finding, previous reports have demonstrated 
that the CCRL2 upregulation through an undefined 
ligand contributes to glioblastoma cell migration [22] 
and colorectal metastasis [23]. By contrast, CCRL2 
overexpression was reported to inhibit CCL2-induced 
phosphorylation of p38 MAPK leading to decreased 
chemotaxis and invasion of human breast cancer cells 
[58]. Thus, the involvement of CCRL2 in Chemerin-
induced cell migration, as a key step in tumor progression, 
is still confounding as to different tumor entities. This 
notion is based on the finding that CCRL2 possesses an 
altered amino acid sequence (QRYLVFL in huCCRL2 
and QRYRVSF in mCCRL2 instead of the conserved 
DRYLAIV motif) in the second intracellular loop which 
is essential for signal transduction [24]. In this context, our 
data on GPR1/CCRL2/Chemerin-induced cell migration 
are novel and would fit to the current model of CCRL2 
action, proposed by Zabel and colleagues [24]. The model 
suggests that Chemerin binds to CCRL2 receptors via its 
amino-terminal domain, which in consequence increases 
the abundance of cell surface-bound Chemerin and 
its local concentration. Chemerin then, in a juxtacrine 
fashion, reacts with other Chemerin receptors (e.g. 
CMKLR1 or GPR1) via its free carboxyl-terminal 
residues. More detailed analysis would, however, be 
required to further delineate the exact mechanism whereby 
Chemerin interacts with GPR1 and/or CCRL2 to stimulate 
cSCC migration.
Fourth, we showed that Chemerin triggers the 
mitogen-activated protein kinase (MAPK) signaling 
pathway in CCRL2high GPR1low SCL-1 cells which express 
no detectable CMKLR1 proteins. Previously, Chemerin 
was shown to activate the p38 and ERK1/2 MAPK 
pathways in gastric cancer cells [31], and PI3K, Akt, and 
p38 in CMKLR1-expressing macrophages [59]. In the 
current study, using the GPCR Cignal® Finder array and 
Western blot analysis, the ERK1/2 and JNK emerged as the 
key downstream mediators of Chemerin-induced signaling 
in cSCC cells. This finding indicates that Chemerin, 
depending on the cell type and the receptor expression 
can activate different subtypes of MAPK pathway. The 
involvement of both ERK1/2 and JNK in cell migration 
and invasion is not unexpected and, in fact, has been well-
established in various cancers [60]. We observed that 
the inhibition of ERK1/2 and JNK with small molecule 
inhibitors abolished the migration-promoting potential of 
Chemerin and senescent fibroblast CM in cSCC cells. This 
implies that majorly Chemerin, and possibly other SASP 
factors, reinforce MAPK as a common signaling pathway 
to induce tumor-cell migration. This is a clinically relevant 
finding indicating that the inhibition of the MAPK 
pathway may prevent cSCC migration and metastasis. 
Apart from Chemerin, other SASP factors among 
them RANTES/CCL5 contribute to cSSC cell migration. 
The role of several SASP factors in tumor cell migration 
has previously been investigated. For instance, the two 
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well-known SASP factors, CXCL8/IL-8 and CCL2/
MCP-1, increase the migration of colorectal cancer 
cells [61]. Also, production of a Wnt antagonist named 
sFRP2 released from senescent dermal fibroblasts has 
been reported to decrease β-catenin and microphthalmia-
associated transcription factor (MITF). This in conjunction 
with the loss of the redox effector protein APE1, a 
multifunctional protein with both DNA repair and 
transcriptional regulatory activities, eventually contributes 
to tumor progression and metastasis in melanoma [62].
In summary, we here uncovered the previously 
unreported GPR1/CCRL2/Chemerin axis in cSCC 
tumor cells which - via the interrelated activation of the 
ERK1/2 and JNK- promotes directed migration and most 
likely tumor progression. Given the current demographic 
development, this is particularly relevant as Chemerin is 
up-regulated in senescent fibroblasts in the skin of elderly 
individuals. 
Our findings with the identification of target 
molecules responsible for skin cancer cell migration/
invasion hold substantial promise for the development 
of novel treatment strategies to overcome the deleterious 
effects of SASP in elderly patients.
MATERIALS AND METHODS
Cell lines and primary cells
Human cutaneous squamous cell carcinoma (cSCC) 
lines SCC-12B2 and SCC-13 [63] were kindly provided by 
Dr. J.G. Rheinwald (Harvard Medical School, Boston, MA). 
Human SCC line A431 was purchased from the American 
Type Culture Collection (ATCC, Manassas, VA, USA). 
Human SCL-1 cell line [64] was a gift from 
Dr. P. Boukamp (DKFZ, Heidelberg, Germany). Primary 
human dermal fibroblast (HDF) strains FF95, FFRa and 
FFPia, and primary normal human epidermal keratinocytes 
(NHEKs) were established from the foreskin of healthy 
males having undergone circumcision according to 
the method described earlier [65, 66]. Primary cSCC-
associated stromal fibroblasts were derived from surplus 
material removed from patient biopsies (F-SCC3, 88 
year-old male and F-SCC1160524, 92 year-old male) at 
the University Hospital Zurich, funded by the University 
Research Priority Program (URPP). All patients included 
in this study have signed a patient release form, which has 
been approved by an ethics committee and assigned the 
numbers EK647, and EK800. 
Cell culture
SCL-1, A431, HDFs and cSCC-associated primary 
stromal fibroblasts (F-SCC3 and F-SCC1160524) were 
maintained in Dulbecco’s Modified Eagle’s Medium 
(DMEM; GIBCO-BRL, Germany) supplemented 
with 10% fetal bovine serum (FBS; Biochrom, Berlin, 
Germany), 2 mM L-glutamine (Biochrom), 100 U/ml 
streptomycin and penicillin (Biochrom), which will be 
referred to as “DMEM growth media” throughout the 
manuscript.
NHEKs, SCC12-B2 and SCC13 cells were cultured 
in complete Keratinocyte Growth Medium M2 (#20011; 
Promocell, Heidelberg, Germany). Collagen-coated (3 µg/cm2) 
flasks were used to support the growth of Keratinocytes 
and SCC12B2 cells. All cells were cultured in a humidified 
atmosphere with 5% CO2 and 21% O2 at 37°C.
Conditioned media
Human derma fibroblast cell strains FF95, FFRa and 
FFPia were passaged to reach their replicative senescence 
at cumulative population doublings (CPDs) > 52, 48 and 
42, respectively, when the typical senescence-associated 
characteristics [67] appeared. To prepare the conditioned 
medium (CM), replicative senescent and young (CPD < 22) 
fibroblasts and intrinsically aged cSCC-associated primary 
stromal fibroblasts derived from elderly patients were 
seeded at a density of 1.25 × 104 cells/cm2 in DMEM 
growth media. Conditioned media (CM) were harvested 
from confluent cells after 7 days, centrifuged (5 min, 
400 × g), filtered (0.22 mm) and normalized to 5 × 104 
cells/ml. Aliquots were stored at −80°C until further use.
Human skin samples 
Human skin specimens were collected from old 
(76 ± 10) and young (21 ± 8) healthy individuals and cSCC 
patients (Supplementary Table S1) from the Department 
of Dermatology and Allergic Diseases upon approval by 
the Ulm University ethical committee (assigned number 
155/2012) according to the Declaration of Helsinki 
principles, after informed written consent was obtained.
Cell migration and invasion assays
Transwell® migration assay was performed as earlier 
described [33] with few modifications using Corning® 
inserts (#3422, Corning, NY, USA). Recombinant human 
(rh) Chemerin (#2324-CM/CF) and rh RANTES/CCL5 
(#278-RN/CF) were purchased from R&D Systems 
(Minneapolis, MN, USA). FR180204 (#SML0320) and 
SP600125 (#S5567) were obtained from Sigma-Aldrich 
(St. Luis, MO, USA), and BIRB796 (#SM11) from Cell 
Guidance Systems (St. Luis, MO, USA). Stock solutions 
were prepared at a concentration of 60 mM in Dimethyl 
sulfoxide (DMSO).
In brief, a number of 2×105 cells in 200 µl serum-
free DMEM was placed onto the upper chambers. The 
lower chambers were loaded with 600 µl conditioned 
medium (CM) or chemotaxis factors and incubated 
overnight (14 h) at 37°C and 5% CO2. DMEM containing 
10% fetal bovine serum (FBS) and collagen type I at a 
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concentration of 50 μg/ml served as positive chemotaxis 
controls. DMEM served as a negative control. After 
14 hours incubation, cells were fixed and stained 
using Diff Quik® Stain kit (Medion Diagnostics AG, 
Switzerland). Non-migrated cells were removed from the 
upper chambers using cotton swaps. Perforated filters were 
cut and stuck on slides. Average number of migrated cells 
were counted in five different high-power microscopic 
fields (HPF) (×100 magnification). 
Invasion assay was performed similar to the 
migration assay, with a difference that a layer of BD 
Matrigel™ (#354230, BD Biosciences, USA) was coated 
(100 µl/ well) onto the upper filter of Transwell® chambers 
4 hours prior to experiment. 
Quantitative real-time PCR (qRT-PCR)
Total RNA was extracted and reverse transcribed 
using standard protocols. Human Chemokine and 
Chemokine receptor RT² Profiler™ PCR Array and 
specific QuantiTect primers (Qiagen, Hilden, Germany,) 
for RARRES2, CCRL2; GPR1, CMKLR1, CCR1, CCR2, 
CCR3, CCR4, CCR5, CXCR1 and CXCR2 genes were 
purchased from Qiagen (Supplementary Table S2) and 
used according to the manufacturer’s instructions. 
Immunofluorescence staining
Immunofluorescence staining was performed using 
the previously described standard method [68]. Primary 
antibodies targeting the following proteins were used at 
indicated concentrations: Chemerin (#ab72965, 1:50, 
Abcam, Cambridge, UK), FSP-1 (#GTX62977, 1:200; 
GenetTex, Irvine, CA, USA), Cytokeratin (#M3515, 
1:100, Dako, Bollschweil, Germany), CCRL2 (#ab136057, 
1:100, Abcam). Appropriate isotype controls were used 
to determine the background. The images were acquired 
using AxioVision software (Carl Zeiss Microimaging 
GmbH, Jena, Germany).
Western blotting
Western blot analysis was performed as earlier 
described [68, 69] using antibodies against CCRL2 
(#ab136057, 1:1000, Abcam), total and phosphorylated 
MAPK member proteins (Cell Signaling, Massachusetts, 
USA) including p42/44 (#4695, 1:2000 & #4370, 1:2000), 
SEK1/MKK4 (#3346, 1:1000 & #4514, 1:1000), ATF-2 
(#9226, 1:1000 & #5112, 1:1000), c-Jun (#9165 & #2361, 
1:1000) and p38 (#4511, 1:2000 & #8690, 1:2000).
Flow cytometry
CCRL2, GPR1 and CMKLR1 cell surface 
expression was measured using APC-conjugated anti-
CCRL2 (#FAB23501A, 1:100, R&D Systems), Alexa488-
conjugated anti-GPR1 mAb (#bs-13509R-A488, 1:100, 
Bioss, Woburn, MA, USA) and PE-conjugated CMKLR1 
(#FAB362P, 1:100, R&D systems) according to the 
manufacturer’s recommendations. Appropriate isotype 
controls were used to determine the background. Dead 
cells were excluded by co-staining with SYTOX® Blue 
(Invitrogen, Carlsbad, CA, USA). Flow cytometry was 
performed on FACSCanto II (BD Biosciences) and the 
data were analyzed using FlowJo analysis software 
(TreeStar Inc.).
ELISA
ELISAs for human Chemerin were performed using 
Quantikine ELISA kit (R&D Systems) according to the 
manufacturer’s instructions.
Cignal™ finder GPCR signaling reporter array
The GPCR array (#CCA-109L-2, Qiagen) was used 
according to manufacturer’s protocol. Briefly, SCL-1 
cells were seeded at a density of 4 × 104 cells/well and 
incubated for 18 h at 5% CO2 and 37°C. Following 
transfection, medium was changed to DMEM containing 
40 nM rh Chemerin. After 1h (and 24 h) incubations, cells 
were lysed and luciferase expression was determined using 
Dual-Glo® Luciferase Assay according to manufacturer’s 
instructions (Promega, Madison, WI, USA). 
SiRNA-based knockdown of Chemerin
Fibroblasts (1 × 105 cells/well) were transfected 
with four different silencing RNAs (siRNAs; 30 nM) 
against Chemerin (# GS5919, Qiagen, Supplementary 
Table S3) or scrambled control (#1027280, Qiagen) using 
Lipofectamine RNAi Max Transfection Reagent (#13778, 
Thermo Fisher Scientific, USA). After 42 h and 48 h post 
transfection, quantitative RNA transcripts and secreted 
Chemerin in the supernatants were analyzed, respectively.
ShRNA-mediated knockdown of CCRL2 and 
GPR1 in SCL-1
For the stable knockdown of CCRL2 and GPR1, 
short hairpin RNA (shRNA) plasmids were obtained 
from Genecoepia (Rockville, MD, USA, Supplementary 
Table S4). HEK293T cells (4 × 106 /10cm dish ) were 
transfected with 13 μg shRNA-plasmids along with 8 μg 
psPAX2 and 4 μg pMD2 packaging plasmids (Addgene, 
Cambridge, MA, USA) using TransIT-LTR transfection 
reagent (Mirus Bio LLC , Madison, WI, USA), and 
following manufacturer’s instructions. Virus was collected 
72 hours after transfection, filtered, and stored at 4°C for 
a maximum of one day. The virus titer was assessed and 
normalized based on the viral protein P24 measurements 
using a P24 ELISA kit (XpressBio, USA). A number of 
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2 × 106 SCL-1 cells were transduced using equal virus titer. 
Transduction efficiency was monitored based on eGFP/
mCherry expression, and positively-transduced SCL-1 cells 
were sorted using FACSAria III (BD Biosciences). Knock-
down efficacy was measured using qRT-PCR analysis.
MTT cell viability/proliferation assay
Cell Proliferation Kit I (MTT) (Roche applied 
science; Indianapolis, IN) was used for the quantitation of 
living metabolically active cells as previously described 
[70]. In brief, SCL-1 cells (1 × 104 cells/well) were seeded 
in 96-well plates and serum-starved on the next day. After 
24 hours, media was exchanged with DMEM containing 
rh Chemerin (or DMEM growth media containing MAPK 
inhibitors) and incubated for 14, 24, 36 and 48 hours.
BrdU proliferation assay
The effect of Chemerin on the proliferation of SCL-1 
was examined by measuring BrdU incorporation into newly-
synthesized DNA using immune fluorescence microscopy 
and flow cytometric analysis as described earlier [70].
Statistics
The final results were calculated as mean ± standard 
error (SEM) of three independent experiments. In some 
experiments, one of three independent experiment was 
presented as mean ± standard deviation (SD). Two-
tailed unpaired student t-test and on-way ANOVA with 
Bonferroni post hoc test were performed as appropriate, 
with significance at p ≤ 0.05 using GraphPad Prism 
Software Inc (London, UK) unless otherwise stated.
Abbreviations
ANOVA Analysis of Variance; BrdU 5-bromo-
2′-deoxyuridine; cSCC Cutaneous squamous cell 
carcinoma; CCRL2 Chemokine CC-motif receptor-
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like receptor 1; DMEM Dulbecco’s Modified Eagle’s 
Medium; DMSO Dimethyl sulfoxide; ELISA Enzyme-
linked immunosorbent assay; ERK Extracellular-signal-
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fluorescent protein; GPCRs G-Protein coupled receptors; 
GPR1 G-protein coupled receptor 1; HDF Human 
dermal fibroblast; JNK c-Jun N-terminal kinase; MAPK 
Mitogen-activated protein kinase; NHEKs Normal human 
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